Clinical Trial

Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation

Study acronym: REAL-GREFFE
Recruiting
View on ClinicalTrials.gov →
Summary
The study concerns donors and patients receiving allogeneic stem cell haematopoietic transplantation. The aim of the study is to analyse HSC graft content in immune effector T (naive, memory, activated, exhausted) and immunoregulatory cell subtypes (Tregs, iNKT, MDSC) and correlate the results with post-transplant immune reconstitution of those different cell subtypes and clinical events (graft-versus-host-disease, relapse, infections). An ancillary study will focus on the impact of microbiota dysbiosis on post-transplant immune response and regulatory cell subsets.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2017-11-28; most recent amendment 2019-10-10.
Status change: Not Yet Recruiting → Recruiting 2019-10-10
Trial Details
NCT Number NCT03357172
Lead Sponsor Central Hospital, Nancy, France
Conditions Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment 700 participants
Start Date 2019-10-01
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2019-10-14